ASCO 2021 Prostate Cancer - Results from #40

Viewing 41-60 of 90 articles

ASCO 2021: VISION Study Results – Phase III Study of Lutetium-177-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

ASCO 2021: Differential Responses to Taxanes and PARP Inhibitors in ATM- Versus BRCA2-Mutated mCRPC Patients

ASCO 2021: Prostate Cancer: Rejecting the Biologic Basis for Outcome Disparities

ASCO 2021: Biomarker Analysis of Phase IB Trial of Radium-223 and Niraparib in Patients with mCRPC (NiraRad)

ASCO 2021: Association of ATM Mutations in Metastatic Prostate Cancer with Differential Genomic Alteration Profiles from Homologous Recombination Deficient and Proficient Tumors

ASCO 2021: Analysis of Two Poor Prognosis Subgroups in ACIS Evaluating Apalutamide + Abiraterone Acetate + Prednisone Versus Placebo + Abiraterone Acetate + Prednisone in mCRPC

ASCO 2021: Copy Number Profiles of Primary Tumors for Risk Stratification of Advanced Prostate Cancer: A Biomarker Study Embedded in the Multicenter STAMPEDE Trial

ASCO 2021: Oligometastases in Prostate Cancer: How to Rationally Incorporate Metastasis-Directed Therapy Into Your Practice: International Perspective

ASCO 2021: Oligometastases in Prostate Cancer: How to Rationally Incorporate Metastasis-Directed Therapy into Your Practice: Radiation Oncologist’s Perspective

ASCO 2021: Oligometastases in Prostate Cancer: How to Rationally Incorporate Metastasis-Directed Therapy into Your Practice: Community Perspective

ASCO 2021: Applying the Results of the Phase III VISION Trial, Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer to Clinical Practice - Discussion

ASCO 2021: Medical Oncologist Perspective: The Promise and Limitations of Precision Health in Metastatic Disease

ASCO 2021: Genomic Medicine in Prostate Trials and Treatments

ASCO 2021: Phase III Study of Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)

ASCO 2021: Novel Approaches to Metastatic Prostate Cancer: Are We Making Progress?

ASCO 2021: Phase I Study of 225Ac-J591 for Men with mCRPC

ASCO 2021: COMBAT-CRPC: COncurrent adMinistration of Bipolar Androgen Therapy and nivolumab in men with mCRPC

ASCO 2021: Results of an Ongoing Phase 1/2a Dose Escalation Study of HPN424, a Tri-Specific Half-Life Extended PSMA-Targeting T-Cell Engager, in Patients with mCRPC

ASCO 2021: Phase I Study of CCW702, A Bispecific Small Molecule-Antibody Conjugate Targeting PSMA and CD3 in Patients with mCRPC

ASCO 2021: Oligometastases in Prostate Cancer: How to Rationally Incorporate Metastasis-Directed Therapy into Your Practice

1
2
3
4
5